Berlex, FDA Discuss HRT Patch Data Documentation After "Not Approvable"
Executive Summary
Berlex and FDA are discussing the agency's requirements for data documentation so that the company may resubmit the NDA for its estradiol/levonorgestrel transdermal patch.